deltatrials
Completed PHASE3 NCT00048230

PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

An International, Multi-Center, Randomized, Open-Label Study of PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Sponsor: Millennium Pharmaceuticals, Inc.

Conditions Multiple Myeloma
Interventions bortezomib
Updated 7 times since 2017 Last updated: Jan 12, 2012 Started: Jun 30, 2002 Primary completion: Jul 31, 2004 Completion: Dec 31, 2004

Listed as NCT00048230, this PHASE3 trial focuses on Multiple Myeloma and remains completed. Sponsored by Millennium Pharmaceuticals, Inc., it has been updated 7 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Millennium Pharmaceuticals, Inc.
Data source: Millennium Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands, Ann Arbor, United States, Antwerp, Belgium, Atlanta, United States, Barcelona, Spain, Belfast, Ireland, Bergamo, Italy, Berkeley, United States, Berlin, Germany, Birmingham, United Kingdom and 71 more location s